Nanobiotix Firmly Back In Business As J&J Comes Onboard
Healthcare Major Licenses French Biotech's Radioenhancer
Cash-strapped Nanobiotix has received a major boost with the news that J&J unit Janssen is paying $60m in upfront fees and R&D funding to license NBTXR3, which has the potential to enhance the efficacy of radiotherapy in multiple tumor types including head and neck cancer.
